The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Gene Therapy Bioassays Market Between 2026 And 2030?
The gene therapy bioassays market has seen substantial growth in recent years. This market is anticipated to expand from $1.21 billion in 2025 to $1.41 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.5%. In the past, this growth was primarily due to an increase in gene therapy research programs, the expansion of viral vector manufacturing, rising clinical trial activity, the implementation of standardized bioassay protocols, and heightened regulatory scrutiny on gene therapy products.
The gene therapy bioassays market size is anticipated to experience significant expansion in the upcoming years, projected to reach $2.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. This growth during the forecast period is primarily driven by the escalating commercialization of gene therapies, the increasing need for high-throughput bioassay solutions, the expansion of personalized genetic medicine, rising investments in advanced cell and gene therapy pipelines, and a heightened focus on assay automation and reproducibility. Notable trends for the forecast period include the increasing adoption of cell-based potency assays, a rising demand for viral vector characterization tests, the growing utilization of automated bioassay platforms, the expansion of regulatory-compliant assay validation, and an enhanced emphasis on functional gene expression analysis.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33119&type=smp
What Leading Drivers Are Supporting The Gene Therapy Bioassays Market Expansion?
The rising volume of gene therapy clinical trials is projected to fuel expansion within the gene therapy bioassays market. These trials assess the safety, effectiveness, and biological function of gene-based treatments in human participants. Their proliferation is a result of heightened research and development activities and increased funding from biopharmaceutical firms aiming to satisfy critical medical demands using novel genetic therapies. Gene therapy bioassays are crucial for clinical progression, offering essential analytical evaluations to determine biological activity, potency, safety, and how the treatment works, throughout each developmental stage, with escalating regulatory demands as programs advance through clinical phases. For example, the Bioindustry Association (BIA), a national trade association based in the UK, reported that in January 2026, the UK had 193 ongoing advanced therapy clinical trials, with more than 80% specifically dedicated to gene therapies. Consequently, the substantial increase in gene therapy clinical trials is propelling the growth of the gene therapy bioassays market.
Which Segment Categories Are Included In The Gene Therapy Bioassays Market Segment Analysis?
The gene therapy bioassays market covered in this report is segmented –
1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types
2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services
3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications
4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories
Subsegments:
1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays
2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays
3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays
4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays
What Emerging Trends Are Seen In The Gene Therapy Bioassays Market?
Major companies operating in the gene therapy bioassays market are increasingly integrating artificial intelligence and machine learning into bioassay analysis, such as AI-enabled digital PCR data interpretation. This focus is aimed at enhancing accuracy, reducing experimental variability, accelerating result turnaround, and optimizing the assessment of therapeutic efficacy and safety in gene therapy development. AI-enabled dPCR data interpretation utilizes advanced algorithms to automate the analysis of results, distinguish true signals from background noise, and precisely quantify viral genomes or vector copy number with minimal human intervention. For instance, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, launched expanded QIAcuity lentivirus solutions, which include the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions offer algorithm-driven absolute quantification, multiplex and singleplex assay compatibility for vector genome and vector copy number analysis, and software-assisted data analysis workflows specifically designed to support regulatory-compliant decision-making in gene therapy bioassay applications.
Who Are The Active Companies Shaping The Gene Therapy Bioassays Market?
Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories
Get The Full Gene Therapy Bioassays Market Report:
https://www.thebusinessresearchcompany.com/report/gene-therapy-bioassays-market-report
Which Region Leads The Gene Therapy Bioassays Market In Terms Of Market Share?
North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy bioassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Gene Therapy Bioassays Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33119&type=smp
Browse Through More Reports Similar to the Global Gene Therapy Bioassays Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Cell And Gene Therapy Clinical Trial Services Market Report 2026
Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model